Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
April 25, 2024 at 06:32 AM EDT
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.